248 related articles for article (PubMed ID: 27220761)
1. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
Xu C; Tang X; Qu Y; Keyoumu S; Zhou N; Tang Y
Cancer Chemother Pharmacol; 2016 Jul; 78(1):119-30. PubMed ID: 27220761
[TBL] [Abstract][Full Text] [Related]
2. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
[TBL] [Abstract][Full Text] [Related]
3. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
[TBL] [Abstract][Full Text] [Related]
4. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.
Marcuello E; Altés A; Menoyo A; Del Rio E; Gómez-Pardo M; Baiget M
Br J Cancer; 2004 Aug; 91(4):678-82. PubMed ID: 15280927
[TBL] [Abstract][Full Text] [Related]
5. [Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].
Boyer JC; Etienne-Grimaldi MC; Thomas F; Quaranta S; Picard N; Loriot MA; Poncet D; Gagnieu MC; Ged C; Broly F; Le Morvan V; Bouquié R; Gaub MP; Philibert L; Ghiringhelli F; Le Guellec C
Bull Cancer; 2014 Jun; 101(6):533-53. PubMed ID: 24977443
[TBL] [Abstract][Full Text] [Related]
6. Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.
Cai X; Cao W; Ding H; Liu T; Zhou X; Wang M; Zhong M; Zhao Z; Xu Q; Wang L
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1579-89. PubMed ID: 23892411
[TBL] [Abstract][Full Text] [Related]
7. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L
Med Oncol; 2013; 30(3):604. PubMed ID: 23686699
[TBL] [Abstract][Full Text] [Related]
8. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
[TBL] [Abstract][Full Text] [Related]
9. UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.
Schulz C; Heinemann V; Schalhorn A; Moosmann N; Zwingers T; Boeck S; Giessen C; Stemmler HJ
World J Gastroenterol; 2009 Oct; 15(40):5058-66. PubMed ID: 19859999
[TBL] [Abstract][Full Text] [Related]
10. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY
Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105
[TBL] [Abstract][Full Text] [Related]
11. The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.
Sugiyama T; Hirose T; Kusumoto S; Shirai T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
Oncol Res; 2010; 18(7):337-42. PubMed ID: 20377135
[TBL] [Abstract][Full Text] [Related]
12. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Liu D; Li J; Gao J; Li Y; Yang R; Shen L
BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
[TBL] [Abstract][Full Text] [Related]
13. Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.
Yu QQ; Qiu H; Zhang MS; Hu GY; Liu B; Huang L; Liao X; Li QX; Li ZH; Yuan XL
World J Gastroenterol; 2016 Apr; 22(16):4250-8. PubMed ID: 27122675
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
[No Abstract] [Full Text] [Related]
15. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
Font A; Sánchez JM; Tarón M; Martinez-Balibrea E; Sánchez JJ; Manzano JL; Margelí M; Richardet M; Barnadas A; Abad A; Rosell R
Invest New Drugs; 2003 Nov; 21(4):435-43. PubMed ID: 14586211
[TBL] [Abstract][Full Text] [Related]
16. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Massacesi C; Terrazzino S; Marcucci F; Rocchi MB; Lippe P; Bisonni R; Lombardo M; Pilone A; Mattioli R; Leon A
Cancer; 2006 Mar; 106(5):1007-16. PubMed ID: 16456808
[TBL] [Abstract][Full Text] [Related]
17. [Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms].
Li H; Huang H; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):888-91. PubMed ID: 22333276
[TBL] [Abstract][Full Text] [Related]
18. Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients.
Gao J; Zhou J; Li Y; Peng Z; Li Y; Wang X; Shen L
Med Oncol; 2013; 30(3):630. PubMed ID: 23783485
[TBL] [Abstract][Full Text] [Related]
19. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
Fakih MG; Ross ME; Starostik P
Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
[TBL] [Abstract][Full Text] [Related]
20. UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
Peng H; Duan Z; Pan D; Wen J; Wei X
Clin Lab; 2017 Sep; 63(9):1339-1346. PubMed ID: 28879724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
